8-KLeadership ChangesExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Executive Changes (Nov 14, 2014)

Filed November 14, 2014For Securities:EW

Summary

This 8-K filing from Edwards Lifesciences Corporation (EW) primarily reports on a key change in its Board of Directors. Effective November 13, 2014, Nicholas J. Valeriani was appointed to the Board and will also serve on the Compensation and Governance Committee. Mr. Valeriani brings a wealth of experience, having served as CEO of the Gary and Mary West Health Institute and spending 34 years at Johnson & Johnson, including on its executive committee. This appointment is significant for investors as it signals the addition of a seasoned executive with extensive experience in the healthcare and medical device industry to the company's leadership oversight. His background in healthcare cost-effectiveness and large-scale corporate management at Johnson & Johnson is likely to be a valuable asset to Edwards Lifesciences' strategic direction and corporate governance. Investors should note that Mr. Valeriani will receive standard compensation for non-employee directors and there are no unusual arrangements associated with his appointment.

Key Highlights

  • 1Nicholas J. Valeriani appointed to the Edwards Lifesciences Board of Directors, effective November 13, 2014.
  • 2Mr. Valeriani will serve on the Compensation and Governance Committee of the Board.
  • 3Mr. Valeriani has significant experience, including CEO of Gary and Mary West Health Institute and 34 years at Johnson & Johnson.
  • 4His background includes executive committee experience at Johnson & Johnson.
  • 5Mr. Valeriani will receive compensation consistent with other non-employee directors.
  • 6No arrangements or understandings exist between Mr. Valeriani and others regarding his selection.
  • 7Mr. Valeriani has no direct or indirect material interest in any transaction requiring disclosure.

Frequently Asked Questions

Nicholas J. Valeriani is a seasoned executive who was appointed to Edwards Lifesciences' Board of Directors. He has been the Chief Executive Officer of the Gary and Mary West Health Institute since 2012 and previously spent 34 years at Johnson & Johnson, where he was a member of its executive committee. This extensive experience in healthcare and large corporate management is a key asset he brings to the board.

Mr. Valeriani has been appointed to the Edwards Lifesciences Board of Directors and will also serve on the Compensation and Governance Committee. This committee plays a crucial role in overseeing executive compensation, director compensation, and corporate governance practices.

No, Mr. Valeriani will receive the same compensation as the company's other non-employee directors, as detailed in the company's 2014 Proxy Statement. There are no unique or special compensation packages associated with his appointment.

According to the filing, there are no arrangements or understandings with other persons concerning his selection as a director. Furthermore, Mr. Valeriani has no direct or indirect material interest in any transactions that require disclosure. He will enter into the standard Indemnification Agreement for directors.